MBX Biosciences, Inc.
MBX
$14.89
$1.007.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -63.18% | -88.61% | -90.16% | -- | -- |
| Total Depreciation and Amortization | 41.15% | 62.50% | 55.41% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.85% | -24.19% | 106.36% | -- | -- |
| Change in Net Operating Assets | 163.64% | 1,002.08% | 725.44% | -- | -- |
| Cash from Operations | -65.25% | -80.31% | -71.00% | -- | -- |
| Capital Expenditure | -10.47% | -65.62% | -577.52% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -251.95% | -1,361.40% | -418.61% | -- | -- |
| Cash from Investing | -247.11% | -1,320.80% | -419.27% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 63,913.09% | 20,244.59% | 23,573.21% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -7.31% | -7.31% | -7.31% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -36.65% | -11,941.67% | -14,370.00% | -- | -- |
| Cash from Financing | 254.08% | 237.40% | 238.21% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 271.16% | -127.33% | 198.24% | -- | -- |